Palmoplantar Psoriasis: Epidemiological and Clinical Features and Impact on Quality of Life

Dorsaf Elinkichari; Faten Rabhi; Kahena Jaber; Raouf Dhaoui

doi:10.5826/dpc.1403a191

Palmoplantar Psoriasis: Epidemiological and Clinical Features and Impact on Quality of Life

Authors

Dorsaf Elinkichari Dermatology Department, Military Hospital of Tunis; Faculty of Medicine of Tunis, University of Tunis EL MANAR, Tunisia
Faten Rabhi Dermatology Department, Military Hospital of Tunis; Faculty of Medicine of Tunis, University of Tunis EL MANAR, Tunisia
Kahena Jaber Dermatology Department, Military Hospital of Tunis; Faculty of Medicine of Tunis, University of Tunis EL MANAR, Tunisia
Raouf Dhaoui Dermatology Department, Military Hospital of Tunis; Faculty of Medicine of Tunis, University of Tunis EL MANAR, Tunisia

Keywords:

Psoriasis, Palmoplantar Psoriasis, Keratoderma, Quality of life

Abstract

Introduction: Palmoplantar psoriasis is a rare variant of psoriasis. Its impact on quality of life have been poorly investigated.

Objectives: Our aim was to investigate the prevalence of localized palmoplantar psoriasis (PPP), to assess its severity using the modified-Palmoplantar Pustular Psoriasis Area and Severity Index (m-PPPASI), and to evaluate the correlation with the Dermatology Life Quality Index (DLQI).

Methods: We conducted a descriptive study with prospective data-collection from January to June 2021. We enrolled 223 patients with psoriasis. We excluded patients without palmar/plantar involvement, and those with a body surface area (BSA) greater than or equal to 10%.

Results: We included 33 patients with PPP. This corresponded to a 14.8% prevalence among all psoriasis phenotypes. The mean age was 45 years. The male to female ratio was 2.3. Pruritus was present in 27 cases. The mean m-PPPASI was 11.77. The mean DLQI was 8.33. A significant correlation was found between DLQI and m-PPPASI: Mean DLQI scores for patients with m-PPPASI less than or equal to 10 and m-PPPASI greater than 10 were 5.6 and 11.3, respectively (p=0.002). Only 11.8% of patients with m-PPPASI less than or equal to 10 had a DLQI greater than 10, whereas 50% of those with m-PPPASI greater than 10 had a DLQI greater than 10 (p=0.026).

Conclusions: Based on the present work, we confirm that, although affecting a reduced BSA, PPP is a severe form of psoriasis. We consider the m-PPPASI to be a reliable tool which can be used to assess the severity of PPP.

References

Parisi, R. et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ 369, m1590 (2020).

Merola, J. F., Qureshi, A. & Husni, M. E. Nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. Dermatol. Ther. 31, (2018).

Farley, E., Masrour, S., McKey, J. & Menter, A. Palmoplantar psoriasis: A phenotypical and clinical review with introduction of a new quality-of-life assessment tool. J. Am. Acad. Dermatol. 60, 1024–1031 (2009).

Chung, J. et al. Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis. J. Am. Acad. Dermatol. 71, 623–632 (2014).

Spuls, P., Hadi, S., Rivera, L. & Lebwohl, M. Retrospective analysis of the treatment of psoriasis of the palms and soles. J. Dermatol. Treat. 14, 21–25 (2003).

Gupta, M. A., Schork, N. J., Gupta, A. K., Kirkby, S. & Ellis, C. N. Suicidal ideation in psoriasis. Int. J. Dermatol. 32, 188–190 (1993).

Basavaraj, K. H., Navya, M. A. & Rashmi, R. Stress and quality of life in psoriasis: an update: Stress and psoriasis. Int. J. Dermatol. 50, 783–792 (2011).

Martínez-Ortega, J. M. et al. Quality of life, anxiety and depressive symptoms in patients with psoriasis: A case-control study. J. Psychosom. Res. 124, 109780 (2019).

Kok, Y., Braue, A., Martyres, R. & Varigos, G. Assessing quality of life and depression in psoriasis patients: A cross‐sectional study. Australas. J. Dermatol. 61, (2020).

Pompili, M. et al. Suicide risk and psychiatric comorbidity in patients with psoriasis. J. Int. Med. Res. 44, 61–66 (2016).

Janagond, A. B., Kanwar, A. J. & Handa, S. Efficacy and safety of systemic methotrexate vs. acitretin in psoriasis patients with significant palmoplantar involvement: a prospective, randomized study: Methotrexate vs. acitretin in palmoplantar psoriasis. J. Eur. Acad. Dermatol. Venereol. 27, e384–e389 (2013).

Pettey, Adam. A., Balkrishnan, R., Rapp, S. R., Fleischer, A. B. & Feldman, S. R. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J. Am. Acad. Dermatol. 49, 271–275 (2003).

Ammar, M. et al. CARD14 alterations in Tunisian patients with psoriasis and further characterization in European cohorts. Br. J. Dermatol. 174, 330–337 (2016).

Khandpur, S., Singhal, V. & Sharma, V. K. Palmoplantar involvement in psoriasis: a clinical study. Indian J. Dermatol. Venereol. Leprol. 77, 625 (2011).

Jaworecka, K. et al. Characteristics of Pruritus in Various Clinical Variants of Psoriasis: Results of the Multinational, Multicenter, Cross-Sectional Study. Life 11, 623 (2021).

Sampogna, F. et al. Prevalence of symptoms experienced by patients with different clinical types of psoriasis. Br. J. Dermatol. 151, 594–599 (2004).

Damiani, G. et al. Pruritus characteristics in a large Italian cohort of psoriatic patients. J. Eur. Acad. Dermatol. Venereol. 33, 1316–1324 (2019).

Puig, L. et al. Documento de consenso sobre la evaluación y el tratamiento de la psoriasis moderada/grave del Grupo Español de Psoriasis**El Grupo Español de Psoriasis es un grupo de trabajo de la Academia Española de Dermatología y Venereología, formado por 50 dermatólogos de ámbito hospitalario, con especial dedicación al tratamiento de pacientes con psoriasis, que cooperan en la investigación clínica y terapéutica en el ámbito de esta enfermedad. de la Academia Española de Dermatología y Venereología. Actas Dermo-Sifiliográficas 100, 277–286 (2009).

Strober, B. et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J. Am. Acad. Dermatol. 82, 117–122 (2020).

Brunasso, A., Salvini, C. & Massone, C. Efalizumab for severe palmo-plantar psoriasis: an open-label pilot trial in five patients. J. Eur. Acad. Dermatol. Venereol. 23, 415–419 (2009).

Ara, S., Mowla, M. R., Alam, M. & Khan, I. Efficacy of oral methotrexate (MTX) monotherapy vs oral MTX plus narrowband ultraviolet light B phototherapy in palmoplantar psoriasis. Dermatol. Ther. 33, e13486 (2020).

Miceli, A. & Schmieder, G. J. Palmoplantar Psoriasis. in StatPearls (StatPearls Publishing, Treasure Island (FL), 2021).

Bissonnette, R. et al. Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study: Treatment of palmoplantar psoriasis with infliximab. J. Eur. Acad. Dermatol. Venereol. 25, 1402–1408 (2011).

Callis Duffin, K. et al. Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry. Dermatology 237, 46–55 (2021).

Yavuz Daglioglu, E. B., Cadirci, D. & Aksoy, M. Effects of disease severity on quality of life in patients with psoriasis. Dermatol. Ther. 33, (2020).

Sarıkaya Solak, S. et al. Clinical characteristics, quality of life and risk factors for severity in palmoplantar pustulosis: a cross‐sectional, multicentre study of 263 patients. Clin. Exp. Dermatol. ced.14829 (2021) doi:10.1111/ced.14829.